Worsening of chronic house-dust-mite-induced respiratory allergies: An observational survey in three European countries.
Disease exacerbation
House dust mite
Respiratory allergy
Worsening
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
19
12
2020
revised:
25
05
2021
accepted:
16
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Although respiratory allergies to house dust mites (HDMs) can often be controlled with symptomatic medications, some patients do not achieve satisfactory disease control. To assess fortnightly fluctuations (notably worsening and/or exacerbations) in disease parameters among patients taking only symptomatic medications for HDM allergy. In a 13-month, observational, multicenter survey of adults with a self-reported history of poorly controlled, moderate-to-severe, physician-diagnosed HDM respiratory allergy in France, Italy, and Spain, fortnightly telephone interviews were used to gather information on medication use, symptoms, the disease burden, and medical consultations from late May 2012 to early July 2013. A total of 313 patients completed the study ( In a 13-month survey of patients with HDM allergy in Italy, France, and Spain, the participants' symptom status fluctuated significantly - illustrating the complexity of this condition. Although most participants reported improvements, the "never-improver" profile warrants further investigation. More prominence could be given to symptom control and a low exacerbation risk as treatment goals in allergic rhinitis.
Sections du résumé
BACKGROUND
BACKGROUND
Although respiratory allergies to house dust mites (HDMs) can often be controlled with symptomatic medications, some patients do not achieve satisfactory disease control.
OBJECTIVE
OBJECTIVE
To assess fortnightly fluctuations (notably worsening and/or exacerbations) in disease parameters among patients taking only symptomatic medications for HDM allergy.
METHODS
METHODS
In a 13-month, observational, multicenter survey of adults with a self-reported history of poorly controlled, moderate-to-severe, physician-diagnosed HDM respiratory allergy in France, Italy, and Spain, fortnightly telephone interviews were used to gather information on medication use, symptoms, the disease burden, and medical consultations from late May 2012 to early July 2013.
RESULTS
RESULTS
A total of 313 patients completed the study (
CONCLUSION
CONCLUSIONS
In a 13-month survey of patients with HDM allergy in Italy, France, and Spain, the participants' symptom status fluctuated significantly - illustrating the complexity of this condition. Although most participants reported improvements, the "never-improver" profile warrants further investigation. More prominence could be given to symptom control and a low exacerbation risk as treatment goals in allergic rhinitis.
Identifiants
pubmed: 34306302
doi: 10.1016/j.waojou.2021.100563
pii: S1939-4551(21)00057-0
pmc: PMC8271175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100563Informations de copyright
© 2021 The Authors.
Références
J Allergy Clin Immunol. 1994 Feb;93(2):470-5
pubmed: 8120274
J Asthma Allergy. 2018 Aug 29;11:193-204
pubmed: 30214247
Lancet. 2010 Sep 4;376(9743):826-34
pubmed: 20816549
J Investig Allergol Clin Immunol. 2011;21 Suppl 3:40-5
pubmed: 22185049
Allergy. 1995 Jun;50(6):478-82
pubmed: 7573840
Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):193-206
pubmed: 22507332
Allergy. 2015 May;70(5):474-94
pubmed: 25620381
Hum Vaccin Immunother. 2019;15(12):2896-2902
pubmed: 31070995
Allergy. 2009 Jan;64(1):166-71
pubmed: 19076546
J Asthma. 2014 Feb;51(1):79-83
pubmed: 24131032
J Allergy Clin Immunol. 1993 Apr;91(4):862-7
pubmed: 8473674
J Allergy Clin Immunol. 2014 Aug;134(2):350-9
pubmed: 24522093
BMJ. 2017 Apr 12;357:j1415
pubmed: 28404617
Allergy Asthma Proc. 2001 Jul-Aug;22(4):239-47
pubmed: 11552675
Am Rev Respir Dis. 1991 May;143(5 Pt 1):983-6
pubmed: 2024854
J Allergy Clin Immunol. 2016 Aug;138(2):367-374.e2
pubmed: 27260321
Allergy Asthma Clin Immunol. 2016 Apr 11;12:13
pubmed: 27069487
Trends Mol Med. 2010 Jul;16(7):321-8
pubmed: 20605742
Int Arch Allergy Immunol. 2016;171(3-4):234-240
pubmed: 28049194
Lancet Planet Health. 2018 Jun;2(6):e255-e263
pubmed: 29880157
Allergy. 2007 Dec;62(12):1394-400
pubmed: 17983374
Clin Transl Allergy. 2020 Jul 1;10:27
pubmed: 32626572
J Allergy Clin Immunol. 2016 Feb;137(2):545-58
pubmed: 26522402
J Allergy Clin Immunol. 2012 Apr;129(4):1020-30
pubmed: 22464673
J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3
pubmed: 31627910
J Allergy Clin Immunol. 2021 Mar;147(3):1020-1030.e10
pubmed: 32890575
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48
pubmed: 22386508
Environ Health. 2015 Aug 27;14:71
pubmed: 26310854
J Allergy Clin Immunol. 1982 Mar;69(3):290-6
pubmed: 7061770
Allergy. 2007 Mar;62(3):301-9
pubmed: 17298348
Allergy Asthma Clin Immunol. 2017 Feb 21;13:11
pubmed: 28239397
J Allergy Clin Immunol. 2015 Jul;136(1):38-48
pubmed: 25457152
Allergy. 2017 Oct;72(10):1576-1578
pubmed: 28273339
BMC Pulm Med. 2016 May 23;16(1):85
pubmed: 27215208